Swedish Orphan Biovitrum Acquires Full Rights for Kineret® and Additional Clinical Data for Kepivance®From Amgen (AMGN)
9/9/2013 9:26:19 AM
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that they have
acquired the full rights to develop and commercialize Kineret (anakinra) from
American biotechnology company Amgen for all therapeutic indications. The
revised agreement builds on the previous agreement that gave Sobi rights for
Kineret within the field of Rheumatoid arthritis (RA) and four orphan drug
indications, including Cryopyrin Associated Periodic Syndrome (CAPS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by